Patents by Inventor Louis Frank Stancato

Louis Frank Stancato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS
    Publication number: 20220378745
    Abstract: The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile and pharmaceutically acceptable salts and solvates thereof, that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.
    Type: Application
    Filed: August 15, 2021
    Publication date: December 1, 2022
    Inventor: Louis Frank STANCATO
  • Variants of human BMP7 protein
    Patent number: 11466066
    Abstract: The present invention relates to novel variants of human BMP7 protein. The invention embodies vectors and host cells for the propagation of nucleic acid sequences encoding said proteins and the production thereof. Also disclosed are methods for the treatment of cancer, cartilage damage and degeneration, pain associated with osteoarthritis, or bone healing.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 11, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: James David Pancook, Scott William Rowlinson, Louis Frank Stancato
  • AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA
    Publication number: 20220000855
    Abstract: The present invention provides an inhibitor of Aurora A kinase, Formula (I) illustrated below, or pharmaceutically acceptable salt thereof, for use in treating neuroblastoma.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 6, 2022
    Inventors: Michele Suzanne DOWLESS, Xueqian GONG, Louis Frank STANCATO
  • CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma
    Patent number: 11123326
    Abstract: The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine˜2˜carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventor: Louis Frank Stancato
  • VARIANTS OF HUMAN BMP7 PROTEIN
    Publication number: 20210115100
    Abstract: The present invention relates to novel variants of human BMP7 protein. The invention embodies vectors and host cells for the propagation of nucleic acid sequences encoding said proteins and the production thereof. Also disclosed are methods for the treatment of cancer, cartilage damage and degeneration, pain associated with osteoarthritis, or bone healing.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 22, 2021
    Inventors: James David Pancook, Scott William Rowlinson, Louis Frank Stancato
  • CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas
    Publication number: 20180369202
    Abstract: The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine˜2˜carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.
    Type: Application
    Filed: July 15, 2016
    Publication date: December 27, 2018
    Inventor: Louis Frank Stancato
  • Combination therapy for ovarian cancer
    Patent number: 9844529
    Abstract: The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 19, 2017
    Assignee: Eli Lilly and Company
    Inventors: Edward Michael Chan, Susan Elizabeth Pratt, Louis Frank Stancato
  • Combination Therapy for Ovarian Cancer
    Publication number: 20140302174
    Abstract: The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Edward Michael Chan, Susan Elizabeth Pratt, Louis Frank Stancato